Complete financial analysis of bioAffinity Technologies, Inc. (BIAFW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioAffinity Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Bumyang Construction Co.,Ltd. (002410.KS) Income Statement Analysis – Financial Results
- R.R.SECURITIES LTD. (RRSECUR.BO) Income Statement Analysis – Financial Results
- Shenzhen Fine Made Electronics Group Co., Ltd. (300671.SZ) Income Statement Analysis – Financial Results
- The L.S. Starrett Company (SCXLB) Income Statement Analysis – Financial Results
- Genesis Photonics Inc. (3383.TW) Income Statement Analysis – Financial Results
bioAffinity Technologies, Inc. (BIAFW)
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.53M | 4.80K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 467.00 | 4.82K | 22.24K | 40.28K |
| Gross Profit | 791.62K | 4.34K | -4.82K | -22.24K | -40.28K |
| Gross Profit Ratio | 31.26% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.72M | 1.29M | 1.33M | 1.61M | 1.85M |
| General & Administrative | 0.00 | 2.73M | 880.77K | 994.34K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.79M | 2.73M | 880.77K | 994.34K | 1.20M |
| Other Expenses | 249.59K | -1.87M | 724.93K | -4.28M | 0.00 |
| Operating Expenses | 8.76M | 4.02M | 2.21M | 2.60M | 3.05M |
| Cost & Expenses | 10.51M | 4.02M | 2.21M | 2.60M | 3.09M |
| Interest Income | 122.13K | 46.71K | 424.00 | 1.07K | 2.78K |
| Interest Expense | 37.13K | 2.53M | 1.00M | 382.17K | 214.83K |
| Depreciation & Amortization | 249.59K | 10.18K | 4.82K | 22.24K | 40.28K |
| EBITDA | -7.63M | -5.61M | -2.20M | -6.86M | -3.05M |
| EBITDA Ratio | -301.26% | -121,196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.97M | -4.01M | -2.21M | -2.60M | -3.09M |
| Operating Income Ratio | -314.84% | -83,511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 57.21K | -4.14M | -4.12M | -4.66M | -212.06K |
| Income Before Tax | -7.92M | -8.15M | -6.32M | -7.27M | -3.30M |
| Income Before Tax Ratio | -312.58% | -169,720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 20.99K | 2.46K | 1.95K | 2.75K | 3.20K |
| Net Income | -7.94M | -8.15M | -6.33M | -7.27M | -3.31M |
| Net Income Ratio | -313.41% | -169,771.25% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| EPS Diluted | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| Weighted Avg Shares Out | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Avg Shares Out (Dil) | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
Source: https://incomestatements.info
Category: Stock Reports